FindTrial
Sign In

ADDED EFFECT OF ORAL ADMINISTRATION OF BAKUCHI CHURNA OVER TOPICAL APPLICATION OF GAJALINDALEPA IN THE MANAGEMENT OF VITILIGO IN CHILDREN

ADDED EFFECT OF ORAL ADMINISTRATION OF BAKUCHI CHURNA OVER TOPICAL APPLICATION OF GAJALINDALEPA IN THE MANAGEMENT OF SWITRA (VITILIGO) IN CHILDREN

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/023946
Enrollment
30
Registered
2020-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Internal administration of BakuchiChurna and External application of Gajalindalepa: Internal administration of BakuchiChurna 0.5 and 1g divided dose for age 6-10 and 11-16 respectively

Sponsors

SRI DHARMASTHALA MANJUNATHESHWARA COLLEGE OF AYURVEDA AND HOSPITAL HASSAN
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.The children of either gender between the age group of 6-16 years fulfilling the diagnostic criteria of Vitiligo. 2.Children, whose parents are willing to participate them in the study after giving informed parental consent.

Exclusion criteria

Exclusion criteria: 1.Vitiligo patches developed as a complication of burns. 2.Children diagnosed with autoimmune disorders, neurological disorders, endocrine disorders, leprosy and tuberculosis. 3.Children with universal vitiligo and mucosal vitiligo.

Design outcomes

Primary

MeasureTime frame
ADDED EFFECT OF ORAL ADMINISTRATION OF BAKUCHI CHURNA OVER TOPICAL APPLICATION OF GAJALINDALEPA IN THE MANAGEMENT OF SWITRA (VITILIGO) IN CHILDRENTimepoint: 60 days of treatment—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr NIDHIN P

SRI DHARMASTHALA MANJUNATHESHWARA COLLEGE OF AYURVEDA AND HOSPITAL HASSAN

rao.shaila@gmail.com9448816433

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026